What diseases does Eltrombopag ethanolamine tablets treat?

Eltrombopag ethanolamine tablets (trade name: Revlan® ) are mainly used to treat specific diseases due to thrombocytopenia and clinical conditions that increase the risk of bleeding.

1. Chronic immune (idiopathic) thrombocytopenia (ITP)

Indications: Suitable for patients with chronic immune (idiopathic) thrombocytopenia (ITP) in adults (≥18 years old) and children 6 years old and above who have had poor response to glucocorticoids, immunoglobulins, etc. in the past.

Mechanism of action: Eltrombopag ethanolamine tablets are an oral thrombopoietin receptor agonist. By activating the thrombopoietin receptor, it promotes the proliferation and differentiation of megakaryocytes in the bone marrow, thereby increasing platelet production.

Clinical effect: It can increase the patient's platelet count, reduce or prevent bleeding, and help improve the clinical symptoms and quality of life ofITP patients.

2. Other thrombocytopenia

Indications: Eltrombopag ethanolamine tablets can also be used to treat other thrombocytopenia caused by different causes, such as adjuvant supportive treatment of thrombocytopenia in patients with low-risk, intermediate-risk 1-2 and high-risk 1 myelodysplastic syndrome, as well as thrombocytopenia associated with solid tumor-related anemia, etc.

Mechanism of action: Also promotes platelet production by activating thrombopoietin receptors.

Clinical effect: Depending on the specific condition and individual patient differences, Eltrombopag ethanolamine tablets may increase the patient's platelet count and improve bleeding symptoms to a certain extent.

3. Thrombocytopenia caused by chemotherapy

Indications: In some patients with advanced malignant tumors, the risk of bleeding may increase due to low platelets caused by radiotherapy, chemotherapy or targeted drug therapy. At this time, Eltrombopag ethanolamine tablets can be used under the guidance of a doctor to help increase the number of platelets and reduce the probability of adverse events.

Mechanism of action: By promoting the production of platelets in the bone marrow, it counteracts the inhibitory effect of chemotherapy drugs on the hematopoietic function of the bone marrow.

Clinical effect: Helps reduce thrombocytopenia caused by chemotherapy, reduces the risk of bleeding, and ensures the smooth progress of chemotherapy.